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Expanded Abstract 
Citation 
A randomized trial of diagnostic techniques for ventilator-
associated pneumonia. N Engl J Med 2006, 355:2619-2630 
[1]. 
Background 
Critically ill patients who require mechanical ventilation are 
at risk for ventilator-associated pneumonia. Current data are 
conflicting as to the optimal diagnostic approach in patients 
who have suspected ventilator-associated pneumonia.     
Methods 
Objective: To compare the quantitative culture of 
bronchoalveolar-lavage fluid and nonquantitative culture of 
endotracheal aspirate in critically ill patients with suspected 
ventilator-associated pneumonia, testing the hypothesis that 
bronchoscopy with quantitative culture would be associated 
with lower mortality rates and less use of antibiotics. 
Design:  Multi-center non-blinded randomized controlled 
trial. 
Setting: 28 intensive care units (ICUs) across Canada and 
the United States. 
Subjects: 740 immunocompetent critically ill adult patients 
with suspected ventilator-associated pneumonia after 4 
days in the ICU. Patients known to be colonized or infected 
with  Pseudomonas species or methicillin-resistant 
Staphylococcus aureus were excluded. 
Intervention: Using a 2-by-2 factorial design, subjects were 
randomly assigned to a) undergo bronchoalveolar lavage 
with quantitative culture of the bronchoalveolar-lavage fluid 
or endotracheal aspiration with nonquantitative culture of 
the aspirate, and to b) receive empirical combination 
antibiotic therapy or monotherapy. Empirical antibiotic 
therapy was initiated in all patients until culture results were 
available, at which point a protocol of targeted therapy was 
used for discontinuing or reducing the dose or number of 
antibiotics, or for resuming antibiotic therapy to treat a pre-
enrollment condition if the culture was negative.    
Outcome:  The primary outcome was 28-day mortality. 
Secondary outcomes included ICU and hospital survival, 
duration of mechanical ventilation, response to clinical and 
microbiologic treatment, discontinuation of antibiotics after 
culture results known, and other measures of antibiotic use. 
Results  
There was no significant difference in 28-day mortality rate 
between the bronchoalveolar-lavage group and the 
endotracheal-aspiration group (18.9% and 18.4%, 
respectively; P=0.94). The bronchoalveolar-lavage group 
and the endotracheal-aspiration group also had similar rates 
of targeted therapy (74.2% and 74.6%, respectively; 
P=0.90), days alive without antibiotics (10.4+/-7.5 and 
10.6+/-7.9, P=0.86), and maximum organ-dysfunction 
scores (mean [+/-SD], 8.3+/-3.6 and 8.6+/-4.0; P=0.26). The 
two groups did not differ significantly in the length of stay in 
the ICU or hospital. 
Conclusions 
Two diagnostic strategies for ventilator-associated 
pneumonia--bronchoalveolar lavage with quantitative 
culture of the bronchoalveolar-lavage fluid and endotracheal 
aspiration with nonquantitative culture of the aspirate--are 
associated with similar clinical outcomes and similar overall 
use of antibiotics. (Current Controlled Trials number, 
ISRCTN51767272.) 
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Commentary 
Ventilator-associated pneumonia (VAP) is common, costly, 
and associated with increased morbidity and mortality. 
Diagnosis of VAP is based on clinical suspicion and 
microbiologic confirmation of a sample obtained from the 
lower respiratory tract. Several methods are available to 
sample lower respiratory tract secretions, including “non-
invasive” sampling via endotracheal aspirate (ETA) and 
“invasive” sampling via bronchoscopy using either a 
protected specimen brush or bronchoalveolar alveolar 
lavage (BAL). Debate exists regarding the best sampling 
approach. However, in the absence of a gold standard to 
diagnose VAP, a rigorous comparison of different diagnostic 
techniques is challenging [2]. Therefore, focus has shifted to 
evaluating the effects of different diagnostic strategies on 
clinical outcomes, such as use of antibiotics, length of stay, 
and mortality.  
Randomized trials comparing invasive versus non-invasive 
approaches have produced conflicting results. Three small 
(n<100) single center trials suggest no difference in 
mortality for patients managed using invasive versus non-
invasive approaches [3-5]. Yet, these studies were 
underpowered to detect differences in mortality. In contrast, 
a large multi-center French study of 413 patients with 
suspected VAP showed that an invasive approach reduced 
14-day mortality, organ dysfunction, and antibiotic use [6].  
In the current study, the Canadian Critical Care Trials Group 
conducted the largest randomized trial to date comparing 
invasive and noninvasive VAP diagnostic techniques [1]. 
This is a multi-center trial in 740 patients with suspected 
VAP in which they tested the hypothesis that quantitative 
culture of BAL fluid would be associated with lower mortality 
rates and increased use of targeted antibiotic therapy 
compared to non-quantitative cultures using ETA. 
Importantly, patients known to be colonized or infected with 
pseudomonas species or methicillin-resistant 
Staphalococus. aureus (MRSA) were excluded. Once 
diagnostic sampling was performed, subjects were 
randomly assigned to one of two empiric antibiotic 
regimens, meropenem and ciprofloxacin vs. meropenem 
alone, in a two-by-two factorial design. Antibiotics were then 
adjusted by the clinical team once culture results were 
known. There were no differences between diagnostic 
strategy groups for either clinical outcomes (28-day 
mortality, organ dysfunction scores, or length of say) or 
measures of antibiotic use. The initial empiric antibiotic(s) 
subjects were randomized to did not alter these findings. 
Why did these two large seemingly similar multi-center 
studies yield different results [1,6]? It is important to 
recognize differences in the study design between the 
French and Canadian studies. The criteria to initiate and de-
escalate antibiotic therapy differed. In the French study, 
initial antibiotic therapy, including the decision to withhold all 
antibiotics, was guided by the results of the Gram-stained 
respiratory specimen. If no organisms were present and 
there were no signs of severe sepsis, antibiotics could be 
withheld. The Canadian study used broad spectrum initial 
antibiotic therapy in all subjects. This practice to administer 
prompt antibiotics in patients suspected to have VAP is 
consistent with current guidelines, though the use of broad 
spectrum antibiotics in patients at low risk of Pseudomonas 
or MRSA infections is not recommended [7]. It is therefore 
not surprising that the initial antibiotic strategy was judged 
as adequate (based on organism cultured) in nearly 90% of 
subjects in the Canadian study, irrespective of diagnostic 
strategy. This is in contrast to the French study, where the 
cultured organism(s) was not susceptible to initial antibiotic 
therapy in 1% of the invasive group, but 13% of the non-
invasive group (p<0.001). Furthermore, because antibiotics 
could be withheld in the French study, it is also not 
surprising that this study showed reduced antibiotic use with 
an invasive approach, while the Canadian study did not. 
Another key difference between the two studies is the 
eligibility criteria. In the Canadian study, excluded were 
patients known to be colonized or infected with 
pseudomonas species or MRSA, pathogens which were 
likely not susceptible to their initial empiric antibiotic 
regimens. The authors note this was to permit 
standardization of empirical antibiotic treatment such that 
any differences in observed outcomes could be better 
attributed to the diagnostic strategy. As pointed out by 
others, patients at risk for infection with these pathogens 
may be the ones most likely to benefit from an invasive 
diagnostic approach [8]. Though there is some face-validity 
to this argument, it remains unproven. Interestingly, in a pre-
specific subgroup analysis, the authors of the Canadian 
study found a non-significant tendency toward increased 
mortality in the invasive group when these high-risk 
pathogens were present. 
These studies yet again emphasize that no diagnostic test, 
whether it be a thermometer, pulmonary artery catheter, 
bronchoscope, or biomarker, will improve outcomes unless 
its provides data that drives management decisions that in 
turn improve outcomes. 
Recommendation 
Current evidence does not support use of invasive 
techniques over non-invasive approaches to diagnose VAP 
in most patients [9,10], with the possible exception of those 
at high risk of multi-drug resistant infections. It is important 
to remember that the most important strategy is to initiate 
prompt, appropriate antimicrobial therapy when VAP is 
suspected and to de-escalate or adjust the therapy as soon 
as culture results become available [7]. 
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